Aprea Therapeutics (APRE): Director received 13K units
Michael Grissinger, Director at Aprea Therapeutics, reported a grant / award of 13K units.
- 13K
- Derivative units
- Traded
- Jun 16, 2026
- Filed
- Jun 17, 2026
The story around this disclosure
Every dated public record OQRO holds about the company from 60 days before to 120 days after, oldest first. It shows what was going on; none of it is a stated reason for the trade.
- May 13, 2026Company filing · Form 8-K · Results, Other newsReported its results, and reported other company news
What came next
- Jul 23, 2026Company filing · Form 8-K · Listing noticeReceived a notice from its stock exchange“On July 23, 2026, Aprea Therapeutics, Inc. (the “Company”) received a notification letter from The Nasdaq Stock Market LLC (“Nasdaq”) informing the Company that, while the Company has not yet regained compliance with the $1.00 minimum bid price required for continued listing on The Nasdaq Capital Market under Nasdaq Listing Rule 5550(a)(2) (the “Minimum Bid Price Requirement”), Nasdaq has determined that the Company…”
- Aug 12, 2026Company filing · Form 8-K · Results, Other newsReported its results, and reported other company news
How to read SEC Form 4
Form 4 is the filing that officers, directors and owners of more than 10% of a US-listed company must send to the SEC within two business days after they buy, sell or otherwise change their holding of the company's stock.
Full guide: What is an SEC Form 4?
What else is on file for Aprea Therapeutics
OQRO holds no insider, Congress, fund or contract record for Aprea Therapeutics dated in the last 90 days.
These are records OQRO holds, counted by their date, not a measure of how much trading took place. Routine paperwork such as option exercises and tax withholding is left out. Everything for the company is on its APRE page.
How this filing works
Explore the data
Other disclosures at Aprea Therapeutics
- SEC Form 4Feb 2, 2026
- SEC Form 4Feb 2, 2026
- SEC Form 4Dec 11, 2025
- SEC Form 4Dec 11, 2025
- SEC Form 4Apr 4, 2025
- SEC Form 4Apr 4, 2025
Everything OQRO holds on this company is on its APRE page.
This is one filing. OQRO holds the rest
Insider trades filed with the SEC, stock trades disclosed by members of Congress, fund holdings from 13F filings and federal contract awards, each one in plain words next to its official filing. On this page it opens why the trade stands out, what the company did around that time, the price since, and every field of the form.
OQRO is free for everyone. No card, no trial
OQRO describes public disclosures and context calculated from them. It does not give personalized advice and does not recommend any transaction. How OQRO treats data